New Anticoagulant Prompts Bad Blood Between Partners

摘要

When scientists from Yale University and a small San Diego-based biotechnology company joined forces in 1993, it seemed like a perfect marriage. The two were bound by a strong common interest: The Yale group wanted to develop a vaccine to protect an estimated 1 billion people infected by a bloodsucking intestinal parasite, the hookworm; and researchers at the company, Corvas International Inc., were hoping to isolate a hookworm protein that could compete in the lucrative anticoagulant drug market.